Last10K.com

Aduro Biotech, Inc. (ADRO) SEC Filing 10-Q Quarterly report for the period ending Tuesday, March 31, 2020

SEC Filings

ADRO Quarterly Reports

    10-Q Quarterly Report August 2020
  • 10-Q Quarterly Report May 2020
  • 10-Q Quarterly Report November 2019
    10-Q Quarterly Report August 2019
    10-Q Quarterly Report May 2019
    10-Q Quarterly Report October 2018

Aduro Biotech, Inc.

CIK: 1435049 Ticker: ADRO

 

 

Exhibit 99.1

 

Contact:

Noopur Liffick

Investor Relations & Corporate Affairs

510-809-2465

investors@aduro.com

press@aduro.com

Aduro Biotech Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results

BERKELEY, California, March 9, 2020 – Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2019.

 

“2019 was a critical year for Aduro as we narrowed the focus of our STING program to squamous cell carcinoma of the head and neck and non-muscle invasive bladder cancer, and shifted the focus of our APRIL program to IgA nephropathy. In an effort to ensure we have the appropriate resources in place to advance these programs, we scaled down the company with the strategic reset in January 2019 and corporate restructuring in January 2020,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “Our strong cash position, which now takes us into 2023, enables us to execute on several key milestones in 2020 across our STING and APRIL programs.”

 

Key Accomplishments in Fiscal Year 2019

 

STING

 

 

First patient dosed in Phase 2 clinical trial of ADU-S100 (MIW815) in combination with Keytruda® (pembrolizumab), an approved anti-PD-1 antibody, as a first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma

 

 

Presented findings from the Phase 1b study of ADU-S100 (MIW815) in combination with spartalizumab (PDR001) in patients with advanced, metastatic treatment-refractory solid tumors or lymphomas in an oral presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

 

 

Presented nonclinical data on the role of TNF-alpha in suppressing the immunogenicity of STING agonists at the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting

 

 

Presented three abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2019, including updated preclinical data on ADU-S100

 

 

APRIL

 

Completed treatment of all healthy volunteer dose cohorts in the single ascending dose and multiple ascending dose portions of the Phase 1 clinical trial of BION-1301 for the treatment of IgA nephropathy

 

 

Presented findings from the dose escalation portion of the Phase 1/2 study of BION-1301 in patients with relapsed or refractory multiple myeloma in two poster presentations at the 2019 ASCO Annual Meeting

 


The following information was filed by Aduro Biotech, Inc. (ADRO) on Monday, March 9, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Aduro Biotech, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Aduro Biotech, Inc..

Continue

Assess how Aduro Biotech, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Aduro Biotech, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
Other
Filter Subcategory:
All
Expense
Product
Geography
Shares
Income
Other
Inside Aduro Biotech, Inc.'s 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets (Unaudited)
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Comprehensive Loss (Unaudited)
Condensed Consolidated Statements Of Comprehensive Loss (Unaudited) (Parenthetical)
Condensed Consolidated Statements Of Operations (Unaudited)
Condensed Consolidated Statements Of Stockholders' Equity (Unaudited)
Balance Sheet Components
Balance Sheet Components (Tables)
Balance Sheet Components - Additional Information (Details)
Balance Sheet Components - Summary Of Accrued Expenses And Other Liabilities (Details)
Balance Sheet Components - Summary Of Property And Equipment, Net (Details)
Basis Of Presentation, Use Of Estimates And Recent Accounting Pronouncements
Basis Of Presentation, Use Of Estimates And Recent Accounting Pronouncements (Policies)
Collaboration Agreements
Collaboration Agreements - Additional Information (Details)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Additional Information (Details)
Commitments And Contingencies - Schedule Of Additional Information Related To Operating Leases (Details)
Commitments And Contingencies - Schedule Of Maturity Of Company's Operating Lease Liabilities (Details)
Commitments And Contingencies - Schedule Of Supplemental Disclosure Cash Flow Related To Operating Leases (Details)
Common Stock
Common Stock (Tables)
Common Stock - Additional Information (Details)
Common Stock - Schedule Of Common Share Reserved For Future Issuance (Details)
Equity Incentive Plans
Equity Incentive Plans (Tables)
Equity Incentive Plans - Additional Information (Details)
Equity Incentive Plans - Schedule Of Black-Scholes Option-Pricing Model (Details)
Equity Incentive Plans - Summary Of Restricted Stock Unit Or Rsu Activity (Details)
Equity Incentive Plans - Summary Of Stock Option Activity (Details)
Equity Incentive Plans - Summary Of Stock Option Activity (Parenthetical) (Details)
Equity Incentive Plans - Summary Of Stock-Based Compensation Expense Recognized For Employees And Non-Employees (Details)
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements - Additional Information (Details)
Fair Value Measurements - Financial Assets And Liabilities Measured At Fair Value On A Recurring Basis (Details)
Fair Value Measurements - Schedule Of Changes In Fair Value Of Liability For Contingent Consideration (Details)
Fair Value Measurements - Summary Of Amortized Cost And Estimated Fair Value Of Available-For-Sale Marketable Securities By Contractual Maturity (Details)
Fair Value Measurements - Summary Of Changes In Fair Value Of Level 3 Financial Liabilities (Details)
Fair Value Measurements - Summary Of Estimated Value Of Cash, Cash Equivalents And Marketable Securities And Gross Unrealized Holding Gains And Losses (Details)
Goodwill And Intangible Assets
Goodwill And Intangible Assets (Tables)
Goodwill And Intangible Assets - Additional Information (Details)
Goodwill And Intangible Assets - Schedule Of Finite-Lived Intangible Assets Estimated Future Amortization Expense (Details)
Goodwill And Intangible Assets - Schedule Of Goodwill (Details)
Goodwill And Intangible Assets - Schedule Of Intangible Assets (Details)
Income Taxes
Income Taxes - Additional Information (Details)
Net Loss Per Common Share
Net Loss Per Common Share (Tables)
Net Loss Per Common Share - Schedule Of Potentially Dilutive Securities Not Included In Calculation Of Diluted Per Common Share (Details)
Organization And Nature Of Business
Organization And Nature Of Business - Additional Information (Details)
Restructuring And Related Expense
Restructuring And Related Expense (Tables)
Restructuring Expense - Additional Information (Details)
Restructuring Expense - Schedule Of Restructuring Expenses (Details)
Ticker: ADRO
CIK: 1435049
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-20-020832
Submitted to the SEC: Mon May 04 2020 4:12:27 PM EST
Accepted by the SEC: Mon May 04 2020
Period: Tuesday, March 31, 2020
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/adro/0001564590-20-020832.htm